Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors—2020 Update

During the last 20 years, chemotherapy has improved survival rates of colorectal cancer (CRC). However, the majority of metastatic cases do not respond to or progress after first line conventional chemotherapy and contribute to the fatalities of patients with CRC. Insights into the immune contexture...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Gerhard, Benítez-Ribas, Daniel, Sánchez, Ariadna, Balaguer, Francesc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694085/
https://www.ncbi.nlm.nih.gov/pubmed/33142689
http://dx.doi.org/10.3390/jcm9113520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694085/
https://www.ncbi.nlm.nih.gov/pubmed/33142689
http://dx.doi.org/10.3390/jcm9113520

Ejemplares similares